There’s one pharma-linked stock most investors have never heard of. It’s on Josh Brown’s list

West Pharmaceutical reported Q2 sales growth of 13.8% to $872M and adjusted EPS growth of 28.8% to $2.37, beating estimates by $0.29, as high-value components rose 19.4% and GLP-1 products reached 18% of revenue. Management has raised 2026 guidance twice, now projecting $3.345B-$3.38B in sales and $8.85-$9.05 in adjusted EPS, or 21%-24% growth, versus its prior $6.00-$6.20 EPS outlook. WST is up 37% YTD and 45% over 12 months; a break above $383 could mark new 52-week highs, while $350 is the near-term technical support level. The company also repurchased $454M of stock in 1H 2026 and authorized a further $1B buyback.

Analysis

WST’s earnings recovery is increasingly a mix-upgrade story rather than simply GLP-1 volume leverage: premium containment components should carry structurally better pricing, qualification barriers, and operating leverage than legacy standard products. The key question for the next 1-3 months is whether the company can sustain margin conversion as capacity expands; a revenue beat without further gross-margin progression would expose the stock’s premium multiple. Lagarde’s Thermo Fisher operating background also raises the probability of a sharper productivity and portfolio-rationalization agenda, though such benefits are more likely a 6-18 month catalyst than a near-term estimate driver.

The market is likely underappreciating concentration risk embedded in the apparent "picks-and-shovels" diversification. Injectable obesity drugs are not interchangeable from a delivery-system standpoint: shifts toward pens, oral formulations, multi-dose formats, or a major customer’s internalization can change WST’s content-per-dose and mix even if the category grows. AbbVie’s purchase of SmartDose creates a modest strategic overhang as it validates pharma interest in controlling delivery technology; the more relevant read-through is whether other large customers seek supply-chain ownership rather than outsourced device exposure.

At a high earnings multiple after a substantial rerating, WST is no longer a clean value recovery. The favorable setup is continuation only if the next results demonstrate premium-component growth above overall sales and preserve incremental margins; absent that, the stock could retrace toward the prior demand zone quickly as investors reassess durability. Relative to LLY/NVO, WST offers less direct clinical and reimbursement risk, but it has greater sensitivity to customer inventory normalization and packaging-volume timing.

Key Decisions for Investors

• Initiate a tactical long WST only on a confirmed close above $383, targeting $425-$440 over 1-3 months; use a closing stop below $350. This offers roughly 2:1 upside/downside, but avoid chasing a gap-driven breakout before volume and peer confirmation.
• For existing WST exposure, retain a core 6-18 month position but trim if premium-component growth decelerates below low-teens or gross margin fails to hold near current levels at the next earnings print; either would challenge the mix-driven multiple expansion thesis.
• Express the lower clinical-risk delivery-infrastructure view as long WST / short equal-dollar NVO only after WST breaks out; reassess if NVO pricing, volume, or reimbursement trends materially improve. The pair isolates WST execution and component-content gains from obesity-drug demand uncertainty.
• Monitor ABBV’s post-acquisition device strategy and any customer commentary on internal delivery systems. Additional vertical-integration transactions would be a warning signal for WST’s long-duration device moat and should cap position size until customer concentration and contract-duration data are confirmed.